Teva Ends Oncology, Women’s Health R&D Following Strategic Review
This article was originally published in Pharmaceutical Approvals Monthly
The company will focus its R&D resources on central nervous system disorders and respiratory disease, but will end investment in women’s health and oncology.
You may also be interested in...
Teva’s new management has homed in on pain and respiratory disease as two core therapeutic areas. During the firm’s second quarter earnings call, CEO Erez Vigodman gave a sneak peek at his comprehensive portfolio review.
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.